Semaglutide Injection Phase 2 Data Presented at ENDO Demonstrated Significant Weight Loss in Adults With Obesity

Chicago (ots/PRNewswire) -

Oral session #12

Adults with obesity treated with semaglutide 0.4 mg administered
once-daily via subcutaneous injections lost up to 13.8% of their body
weight after 52 weeks in a phase 2 trial, significantly more than
those treated with placebo who lost 2.3% of their body weight.[1] An
oral presentation of data from this trial investigating the safety
and efficacy of semaglutide as a potential treatment for adults with
obesity took place at the Endocrine Society's annual meeting in
Chicago (ENDO).

The results were from a phase 2, 52-week double blind dose-ranging
study of once-daily semaglutide versus placebo and liraglutide 3 mg
as active control. All trial participants also received dietary and
physical exercise counselling.[1]

In the trial, 83% of people treated with semaglutide 0.4 mg lost
greater than or equal to 5% of their body weight (compared to 23%
with placebo and 66% with liraglutide 3 mg) and 65% lost greater than
or equal to 10% (compared to 10% with placebo and 34% with
liraglutide 3 mg).[1]

"In the US alone, more than 90 million adults have obesity. We
need to continue to research and develop new therapies to support
those living with this chronic disease," said Dr Patrick O'Neil of
the Medical University of South Carolina and lead investigator. "I am
encouraged by these results and look forward to seeing data from
upcoming phase 3 trials to better understand how semaglutide may play
a role in the treatment of obesity."

In the trial, the most common adverse events among people treated
with semaglutide were dose-related gastrointestinal events, as seen
previously with GLP-1 receptor agonists.[1]

"In line with our long-term commitment, we plan to start the STEP
phase 3 clinical development programme later this year to explore the
potential of once-weekly semaglutide as a treatment for people with
obesity," said Mads Krogsgaard Thomsen, executive vice president and
chief science officer of Novo Nordisk. "This will also include the
cardiovascular outcomes trial, SELECT, which will investigate the
impact of semaglutide on the incidence of major adverse
cardiovascular events compared to placebo in patients with
established cardiovascular disease and either overweight or obesity."

About the phase 2 clinical trial

The phase 2 trial was a 52-week multinational, double-blind,
dose-ranging study of semaglutide versus placebo and liraglutide 3 mg
as active control. The trial investigated the safety and efficacy of
once-daily semaglutide in 957 adult patients with obesity without
diabetes.

In the trial, adults treated with semaglutide received a
once-daily subcutaneous dose of 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or